October 11, 2016—Embattled EpiPen manufacturer Mylan has agreed to a $465 million settlement with the U.S. Justice Department to resolve claims the company underpaid Medicaid drug rebates by misclassifying EpiPen as a generic rather than brand-name product. It is unclear if the deal will compensate healthcare providers in the 340B drug discount program for Mylan overcharges.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)